非透析慢性腎臓病患者における貧血に対するASP1517の間欠的経口投与に関する研究

基本情報

NCT ID: NCT02988973
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 334
治験依頼者名: Astellas Pharma Inc

概要

The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).

対象疾患

Chronic Kidney Disease

介入

roxadustat(DRUG)

DA(DRUG)

依頼者（Sponsor）

アステラス製薬株式会社(INDUSTRY)

Kyntra Bio(INDUSTRY)